Navigation Links
Test Might Predict Risk of Lung Cancer's Return
Date:1/27/2012

By Randy Dotinga
HealthDay Reporter

THURSDAY, Jan. 26 (HealthDay News) -- A new industry-funded study suggests that a molecular test can provide insight into whether patients are at high risk of a relapse after surgical treatment for a form of lung cancer.

The test, which is currently available, could help doctors decide whether the patients should undergo chemotherapy to prevent the cancer from returning.

There are caveats: The test is expensive, and researchers don't yet know whether patients determined to be at high risk will live longer if they undergo chemotherapy.

Still, "this may be one of the very first examples of where we understood enough about the molecular biology of a cancer to truly personalize the treatment of patients and actually improve the cure rate for that cancer," said study co-author Dr. Michael Mann, an associate professor of surgery at the University of California, San Francisco.

At issue is non-small-cell lung cancer, by far the most common kind of lung cancer. Even if tumors are diagnosed early and removed, the cancer will spread and kill 35 percent to 50 percent of patients.

In these cases, "even when the tumor is small and they got it all, microscopic disease has spread around the body," said Dr. John Minna, co-author of a commentary accompanying the study. He is a cancer researcher and professor of medicine at the University of Texas Southwestern Medical Center in Dallas.

Scientists are trying to find a way to predict what will happen to patients after surgery so they can figure out if chemotherapy treatment is a good idea.

In the new study, researchers gave the molecular test to 433 lung cancer patients in California and 1,006 patients in China. The researchers found that the test helped them to predict the likelihood that patients would survive for five years.

Conceivably, physicians could adjust the treatment of patients after surgery to coincide with the risk of a recurrence of their cancer. For now, though, that's not proven. The research "doesn't tell you that if you had a bad prognosis and you were treated with chemotherapy, then you'd do better," Minna said.

Still, information about the risks faced by a patient could help doctors make choices about treatments, said Minna, who called the test "promising."

Study co-author Mann agreed: "There may be an important conversation that you can have with your oncologist about potential benefit from additional therapy to reduce the likelihood of the cancer coming back."

Mann said the test -- which is currently available -- could cost several thousand dollars. Minna, the commentary co-author, said any cost over a few hundred dollars could be an issue for insurors.

The research was funded by the firm that developed the molecular test, and several of the study authors serve as consultants to the firm.

The study appears in the Jan. 27 online issue of The Lancet.

More information

For more about lung cancer, try the U.S. National Library of Medicine.

SOURCES: Michael J. Mann, M.D., associate professor, surgery, University of California, San Francisco; John D. Minna, M.D., professor, medicine, University of Texas Southwestern Medical Center, Dallas; Jan. 27, 2012, The Lancet


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Herpes Drug Might Also Slow HIV Progression
2. Bonding Hormone Might Help Some With Autism
3. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
4. Bilingualism Might Begin in the Womb
5. Teens Might Exercise More If They Think Its Fun
6. Gas Cooking Might Up Your Cancer Risk
7. Afternoon Nap Might Make You Smarter
8. What it might take to unravel the lean mean machine that is cancer
9. Increasing neurogenesis might prevent drug addiction and relapse
10. Kids Peanut Allergies Might Be Tamed: Study
11. Blood Test Might Sort Out Milk Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Test Might Predict Risk of Lung Cancer's Return
(Date:1/23/2017)... GREENVILLE, SC (PRWEB) , ... January 23, 2017 ... ... which is the premiere organization in North America for the scientific development, healthcare ... its 2017 Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses ...
(Date:1/23/2017)... ... January 23, 2017 , ... Steviva Ingredients, makers of all-natural ... USDA National Organic Program (NOP) for its Portland SQF Level 2 manufacturing facility. ... and handling systems to complement our current rigorous food-safety management systems,” said Yishu ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... general gynecological care and gynecological services for women of all ages. ... for a wide variety of reproductive services from routine health screenings to diagnosing ...
(Date:1/23/2017)... ... ... “Life Under Blankets”: an entrancing story about one woman's travels through the ... creation of published author, Kimberly Mitchell, who earned her bachelor’s degree in English education ... a master’s degree in education in the field of curriculum and instruction. Kimberly’s passion ...
(Date:1/22/2017)... Boca Raton, FL (PRWEB) , ... January 22, 2017 , ... ... products to customers across the world, recently met with big-name retail buyers at the ... strong scientific evidence of efficacy and uses the utmost safety standards in all of ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... N.Y. , Jan. 23, 2017 LifeVac, ... from a blocked airway and prevented choking deaths, welcomes ... awareness advocate to the LifeVac team as Official Spokesperson. ... Steve join the LifeVac team," said Arthur Lih ... positioned to represent LifeVac and his mission to raise ...
(Date:1/23/2017)... , Jan 23, 2017 Research and Markets has ... & Trends - Product - Forecast to 2025" report to their ... Report Highlights: ... future market trends to identify the investment opportunities Market ... Key market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... January 23, 2017 Stock-Callers.com today presents ... (NASDAQ: CPRX ), Sophiris Bio Inc. (NASDAQ: ... ), and Agile Therapeutics Inc. (NASDAQ: AGRX ). ... somewhat lower in late trade on Friday, January 20 th ... 0.3%, while shares of health care companies in the S&P ...
Breaking Medicine Technology: